A randomized, open label, multi-center, comparative trial, to assess the efficacy and safety of Pritelivir versus Foscarnet for the treatment of Acyclovir-resistant mucocutaneous HSV infections in immunocompromised adultsmidwayadmin2019-04-24T18:00:35+00:00
A randomized, open label, multi-center, comparative trial, to assess the efficacy and safety of Pritelivir versus Foscarnet for the treatment of Acyclovir-resistant mucocutaneous HSV infections in immunocompromised adults
AIC316-03-II-01 · Trial ·
Major Inclusion/Exclusion Criteria
- Must be immunocompromised
- HSV lesion with clinical failure 5 days after using acyclovir, valacyclovir, or famciclovir
- HSV lesion accessible for size measurement and photography